ESSA Pharma stock falls 1.85 percent as merger terms change the EPIX reference

ESSA Pharma stock was quoted at USD 0.20 on Nasdaq on October 13, 2025, down 1.85 percent from the previous session. A corporate-action record dated September 24, 2026 sets out a cash and stock merger for holders of the former EPIX security.

Merger terms set a new reference

According to Robinhood, each former ESSA Pharma common share is tied to USD 0.1242 in cash and 1.0000 successor EPIX share. Fractional shares are retained under the recorded transaction terms.

The structure changes the way the old EPIX quote should be read. The USD 0.20 reference price from October 13, 2025 is 61.0 percent above the cash component alone, while the successor-share element represents the remaining transaction value.

Clinical biotech remains the business anchor

ESSA Pharma describes its work as the development of small molecule drugs for cancer treatment, with a research pipeline centered on oncology. Its investor page identifies the company goal as developing therapies for patients and the wider community.

The company profile identifies ESSA Pharma as a clinical-stage biotechnology business focused on prostate cancer. That profile names EPI-7386 as an oral investigational treatment for metastatic castration-resistant prostate cancer and places the company in Vancouver, Canada.

EPIX quote remains a historical marker

The latest structured quote shows USD 0.20, a daily change of minus 1.85 percent, a 52-week range of USD 0.18 to USD 6.45 and market capitalization of USD 9,518,449, all dated October 13, 2025. The merger record dated September 24, 2026 is therefore the more recent company-specific reference for interpreting the security.